Speciality glass
Photo credits: pixabay.com
Commented by Jens Castner on October 30th, 2026 | 05:45 CET
When the stock market gets it wrong: Schott Pharma clears its name; Lahontan Gold and Instone are the next candidates
Markets are quick to judge, and often paint companies with a broad brush. When one company runs into difficulties, its competitors immediately come under suspicion too. Schott Pharma has already been through this and dispelled the doubts with strong figures. Its share price is recovering. For Lahontan Gold and Instone Real Estate, the recovery has yet to come. The Canadian gold explorer is being punished alongside the major producers, while the property developer is being grouped with Berlin's residential landlords. In both cases, the facts tell a different story. The share price upside is considerable.
Read